Synonyms: Acelex® (S. Korea) | CG-100649 | CG100649
polmacoxib is an approved drug
Compound class:
Synthetic organic
Comment: Polmacoxib is a first-in-class dual COX2/carbonic anhydrase I/II inhibitor, a potential non-steroidal anti-inflammatory drug (NSAID) with postulated attenuated cardiovascular risk compared to selective COX2 inhibiting NSAIDs [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Immunopharmacology Comments |
Polmacoxib is the first dual COX2/carbonic anhydrase I/II inhibitor to receive marketing authorisation. |
Immunopharmacology Disease | |||
Disease | X-Refs | Comment | References |
Osteoarthritis |
Disease Ontology:
DOID:8398 |
Approved drug for OA. |